Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure
Top Cited Papers
- 13 February 2017
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 69 (7), 805-819
- https://doi.org/10.1016/j.jacc.2016.11.064
Abstract
No abstract availableThis publication has 41 references indexed in Scilit:
- Proteolytic Processing of Angiotensin-I in Human Blood PlasmaPLOS ONE, 2013
- Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human SubjectsClinical Pharmacokinetics, 2013
- Angiotensin-Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis, and Cardiac DysfunctionCirculation, 2010
- Mast cell chymase limits the cardiac efficacy of Ang I–converting enzyme inhibitor therapy in rodentsJCI Insight, 2010
- Detection of Soluble Angiotensin-Converting Enzyme 2 in Heart Failure: Insights Into the Endogenous Counter-Regulatory Pathway of the Renin-Angiotensin-Aldosterone SystemJournal of the American College of Cardiology, 2008
- Angiotensin-Converting Enzyme C-Terminal Catalytic Domain Is the Main Site of Angiotensin I Cleavage In VivoHypertension, 2008
- Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibitionInternational Journal of Cardiology, 2006
- Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failureEuropean Heart Journal, 2000
- Metabolism of Angiotensin-(1–7) by Angiotensin-Converting EnzymeHypertension, 1998
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureThe New England Journal of Medicine, 1987